191 related articles for article (PubMed ID: 9452481)
21. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
McCarthy KJ; Routh RE; Shaw W; Walsh K; Welbourne TC; Johnson JH
Kidney Int; 2000 Dec; 58(6):2341-50. PubMed ID: 11115068
[TBL] [Abstract][Full Text] [Related]
22. Effects of type-2 diabetes and troglitazone on the expression patterns of small intestinal sugar transporters and PPAR-gamma in the Zucker diabetic fatty rat.
Corpe C; Sreenan S; Burant C
Digestion; 2001; 63(2):116-23. PubMed ID: 11244250
[TBL] [Abstract][Full Text] [Related]
23. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
Brown KK; Henke BR; Blanchard SG; Cobb JE; Mook R; Kaldor I; Kliewer SA; Lehmann JM; Lenhard JM; Harrington WW; Novak PJ; Faison W; Binz JG; Hashim MA; Oliver WO; Brown HR; Parks DJ; Plunket KD; Tong WQ; Menius JA; Adkison K; Noble SA; Willson TM
Diabetes; 1999 Jul; 48(7):1415-24. PubMed ID: 10389847
[TBL] [Abstract][Full Text] [Related]
24. The effect of troglitazone on plasma homocysteine, hepatic and red blood cell S-adenosyl methionine, and S-adenosyl homocysteine and enzymes in homocysteine metabolism in Zucker rats.
Fonseca V; Keebler M; Dicker-Brown A; Desouza C; Poirier LA; Murthy SN; McNamara DB
Metabolism; 2002 Jun; 51(6):783-6. PubMed ID: 12037736
[TBL] [Abstract][Full Text] [Related]
25. Troglitazone (CS-045) normalizes hypertriglyceridemia and restores the altered patterns of glucose-stimulated insulin secretion in dyslipidemic rats.
Chicco A; Basabe JC; Karabatas L; Ferraris N; Fortino A; Lombardo YB
Metabolism; 2000 Oct; 49(10):1346-51. PubMed ID: 11079827
[TBL] [Abstract][Full Text] [Related]
26. Improved metabolic status and insulin sensitivity in obese fatty (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats treated with the thiazolidinedione, MCC-555.
Upton R; Widdowson PS; Ishii S; Tanaka H; Williams G
Br J Pharmacol; 1998 Dec; 125(8):1708-14. PubMed ID: 9886762
[TBL] [Abstract][Full Text] [Related]
27. Impact of alogliptin and pioglitazone on lipid metabolism in islets of prediabetic and diabetic Zucker Diabetic Fatty rats.
Cai Y; Lydic TA; Turkette T; Reid GE; Olson LK
Biochem Pharmacol; 2015 May; 95(1):46-57. PubMed ID: 25801003
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Shibata T; Matsui K; Nagao K; Shinkai H; Yonemori F; Wakitani K
Eur J Pharmacol; 1999 Jan; 364(2-3):211-9. PubMed ID: 9932726
[TBL] [Abstract][Full Text] [Related]
29. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM.
Lee Y; Hirose H; Zhou YT; Esser V; McGarry JD; Unger RH
Diabetes; 1997 Mar; 46(3):408-13. PubMed ID: 9032096
[TBL] [Abstract][Full Text] [Related]
30. Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus.
Furuta M; Yano Y; Gabazza EC; Araki-Sasaki R; Tanaka T; Katsuki A; Hori Y; Nakatani K; Sumida Y; Adachi Y
Diabetes Res Clin Pract; 2002 Jun; 56(3):159-71. PubMed ID: 11947963
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of KATP channel activity by troglitazone in CRI-G1 insulin-secreting cells.
Lee K; Ibbotson T; Richardson PJ; Boden PR
Eur J Pharmacol; 1996 Oct; 313(1-2):163-7. PubMed ID: 8905344
[TBL] [Abstract][Full Text] [Related]
32. Acute exposure of beta-cells to troglitazone decreases insulin hypersecretion via activating AMPK.
Deng R; Nie A; Jian F; Liu Y; Tang H; Zhang J; Zhang Y; Shao L; Li F; Zhou L; Wang X; Ning G
Biochim Biophys Acta; 2014 Jan; 1840(1):577-85. PubMed ID: 24144566
[TBL] [Abstract][Full Text] [Related]
33. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets.
Kakuma T; Lee Y; Higa M; Wang Zw; Pan W; Shimomura I; Unger RH
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8536-41. PubMed ID: 10900012
[TBL] [Abstract][Full Text] [Related]
34. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
Fujiwara T; Yoshioka S; Yoshioka T; Ushiyama I; Horikoshi H
Diabetes; 1988 Nov; 37(11):1549-58. PubMed ID: 3053303
[TBL] [Abstract][Full Text] [Related]
35. Lack of effect of CS-045, a new antidiabetic agent, on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats.
Inoue Y; Tanigawa K; Nakamura S; Xu G; Kawaguchi M; Kato Y; Tamura K
Diabetes Res Clin Pract; 1995 Jan; 27(1):19-26. PubMed ID: 7781490
[TBL] [Abstract][Full Text] [Related]
36. Effect of troglitazone on exocrine pancreas in rats with streptozotocin-induced diabetes mellitus.
Shimizu K; Shiratori K; Hayashi N; Fujiwara T; Horikoshi H
Pancreas; 2000 Nov; 21(4):421-6. PubMed ID: 11075998
[TBL] [Abstract][Full Text] [Related]
37. Low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of Zucker diabetic fatty rats.
MacDonald MJ; Tang J; Polonsky KS
Diabetes; 1996 Nov; 45(11):1626-30. PubMed ID: 8866570
[TBL] [Abstract][Full Text] [Related]
38. Troglitazone action is independent of adipose tissue.
Burant CF; Sreenan S; Hirano K; Tai TA; Lohmiller J; Lukens J; Davidson NO; Ross S; Graves RA
J Clin Invest; 1997 Dec; 100(11):2900-8. PubMed ID: 9389757
[TBL] [Abstract][Full Text] [Related]
39. Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover.
Unger RH; Zhou YT
Diabetes; 2001 Feb; 50 Suppl 1():S118-21. PubMed ID: 11272168
[TBL] [Abstract][Full Text] [Related]
40. Troglitazone improves insulin-stimulated glucose utilization associated with an increased muscle glycogen content in obese Zucker rats.
Oshida Y; Kako M; Nakai N; Shimomura Y; Li L; Sato J; Ohsawa I; Sato Y
Endocr J; 1999 Oct; 46(5):723-30. PubMed ID: 10670760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
